Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032

INTRODUCTION: For patients with recurrent SCLC, topotecan remains the only approved second-line treatment, and the outcomes are poor. CheckMate 032 is a phase 1/2, multicenter, open-label study of nivolumab or nivolumab plus ipilimumab in SCLC or other advanced/metastatic solid tumors previously tre...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:J Thorac Oncol
Main Authors: Ready, Neal, Farago, Anna F., de Braud, Filippo, Atmaca, Akin, Hellmann, Matthew D., Schneider, Jeffrey G., Spigel, David R., Moreno, Victor, Chau, Ian, Hann, Christine L., Eder, Joseph Paul, Steele, Nicola L., Pieters, Anne, Fairchild, Justin, Antonia, Scott J.
Format: Artigo
Sprog:Inglês
Udgivet: 2018
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8050700/
https://ncbi.nlm.nih.gov/pubmed/30316010
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jtho.2018.10.003
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker